Could a forearm shot of naloxone save more lives?

NCT ID NCT07180420

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether injecting naloxone into the forearm works as well as the standard injection into the buttocks. Twelve healthy volunteers received the forearm injection to measure how the drug behaves in the body. The goal is to make naloxone easier to give quickly during an opioid overdose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
naloxone hydrochloride
What this could lead to
If successful, this could allow faster and easier naloxone administration during an opioid overdose, potentially saving more lives.
What could go wrong
This is a very early, small study in healthy volunteers, not people experiencing an overdose. Results may not translate to real-world emergency use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Mar 2024

Finished

Apr 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 55 years of age * Body mass index (BMI) 18 to 30 kg/m2 * Subjects who do not take prescribed or OTC medications on a regular basis. In the case of recent sporadic use for minor illness, the subject may be enrolled if the investigator deems the use insignificant to study. * Nonsmokers and subjects who smoked 10 or fewer cigarettes per day. * Be willing to spend at least 12 hours in the study facility. Exclusion Criteria: * Subjects who do not fulfill criteria as described in Inclusion Criteria above * Abnormal wrist or forearm anatomy (or history of prior wrist/forearm surgery). * Difficult venous access for blood draws * Active infection in including respiratory tract infection * Used opioid analgesics for pain relief within the previous 14 days, or, in the judgment of the investigator, had significant acute or chronic medical conditions. * Known previous or concomitant serious illness or medical condition such as malignancy, HIV, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis that in the opinion of the investigator may interfere with participation in the study * Previous Substance Use Disorder (SUD) with injectable drugs. * Compromised cardiovascular system (history of myocardial infarction- MI, angina, etc., at discretion of principal investigator- PI).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer - complete are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • JCCT

    Lenexa, Kansas, 66219, United States